Phase 1b multicenter study of SG001, a humanized anti-PD-1 antibody, i

Introduction

Blocking programmed cell death protein 1 (PD-1), and its ligand, programmed death ligand-1 (PD-L1), represents a validated therapeutic strategy to increase tumor-specific T-cell activation and antitumor activity across various…